CLINICAL TRIALS PROFILE FOR DIOVAN HCT
✉ Email this page to a colleague
All Clinical Trials for DIOVAN HCT
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00034840 ↗ | Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose | Completed | Bayer | Phase 4 | 2001-10-01 | The primary objectives are to demonstrate that MICARDIS® (telmisartan) is statistically superior to Diovan® (valsartan) in reducing diastolic blood pressure (DBP) following a missed dose at the end of a 6 to 8-week treatment period as measured by the 24-hour ABPM mean and to demonstrate that MICARDIS® is statistically superior to Diovan® in reducing DBP during the last 6-hours of the 24-hour dosing interval as measured by ABPM following a dose of active study medication at the end of a 6 to 8-week treatment period. |
| NCT00034840 ↗ | Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose | Completed | GlaxoSmithKline | Phase 4 | 2001-10-01 | The primary objectives are to demonstrate that MICARDIS® (telmisartan) is statistically superior to Diovan® (valsartan) in reducing diastolic blood pressure (DBP) following a missed dose at the end of a 6 to 8-week treatment period as measured by the 24-hour ABPM mean and to demonstrate that MICARDIS® is statistically superior to Diovan® in reducing DBP during the last 6-hours of the 24-hour dosing interval as measured by ABPM following a dose of active study medication at the end of a 6 to 8-week treatment period. |
| NCT00034840 ↗ | Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose | Completed | Boehringer Ingelheim | Phase 4 | 2001-10-01 | The primary objectives are to demonstrate that MICARDIS® (telmisartan) is statistically superior to Diovan® (valsartan) in reducing diastolic blood pressure (DBP) following a missed dose at the end of a 6 to 8-week treatment period as measured by the 24-hour ABPM mean and to demonstrate that MICARDIS® is statistically superior to Diovan® in reducing DBP during the last 6-hours of the 24-hour dosing interval as measured by ABPM following a dose of active study medication at the end of a 6 to 8-week treatment period. |
| NCT00130156 ↗ | Effects of Combination Therapy With Alpha-1 Blocker (Bunazosin or Doxazosin) in the Treatment of Patients With Mild to Moderate Essential Hypertension | Completed | Eisai Co., Ltd. | Phase 4 | 2005-10-01 | The purpose of this study is to investigate the efficacy and safety of Bunazosin with Valsartin compared to Doxazosin with Valsartin for patients with mild to moderate essential hypertension accompanied by metabolic syndrome. |
| NCT00130156 ↗ | Effects of Combination Therapy With Alpha-1 Blocker (Bunazosin or Doxazosin) in the Treatment of Patients With Mild to Moderate Essential Hypertension | Completed | Eisai Inc. | Phase 4 | 2005-10-01 | The purpose of this study is to investigate the efficacy and safety of Bunazosin with Valsartin compared to Doxazosin with Valsartin for patients with mild to moderate essential hypertension accompanied by metabolic syndrome. |
| NCT00149227 ↗ | Add-on Effects of Valsartan on Morbi- Mortality (KYOTO HEART Study) | Completed | Kyoto Prefectural University of Medicine | Phase 4 | 2004-01-01 | The KYOTO HEART Study is to assess the add-on effect of valsartan, an Angiotensin-Receptor Blocker, on top of the conventional treatment in high risk patients in Japan with hypertension in terms of the morbidity and mortality. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for DIOVAN HCT
Condition Name
Clinical Trial Locations for DIOVAN HCT
Trials by Country
Clinical Trial Progress for DIOVAN HCT
Clinical Trial Phase
Clinical Trial Sponsors for DIOVAN HCT
Sponsor Name
